Current therapy options and clinical outcomes analysis in patients with PV Published 2014-10-02 Download video MP4 360p Download video MP4 720p Recommendations 45:36 Mast Cell Activation Syndrome: The Functional Medicine Approach 03:31 Hematology – Elevated Hemoglobin: By Karima Khamisa M.D. 3:09:54 Hyponatremia 2:25:55 HMS/HSDM White Coat Ceremony 42:15 Optimizing Diagnosis of Malignant Lung Nodules with the Use of Biomarker Testing and Robotic Bronch 1:32:16 An Answer to Cancer? Using the immune system to fight cancer -- Longwood Seminar 2:24:07 2023 HMS/HSDM White Coat Ceremony 28:40 The Business of Weight-Loss Drugs Like Ozempic and Mounjaro | WSJ 1:26:39 Standing on the Shoulders of Giants 12:25 Loser: Why indicted Trump’s fraud loss is higher than many realize 1:44:58 Why Sleep Matters 44:03 EGFR: The Challenge of Primary and Secondary Resistance 1:28:26 Cancer Metabolism: From molecules to medicine 1:30:26 The Science of Pain Management 51:47 Updates in Front-Line Advances in Adjuvant and Targeted Treatment for Endometrial Cancer 22:15 Change Your Diet | Healthy Living - February 20, 2024 13:23 Trump fake elector in Wisconsin describes how he says he was tricked | 60 Minutes 1:33:13 Unlock Updated Guidelines for the Treatment of RRMM 1:23:46 MD vs. Machine: Artificial intelligence in health care 47:55 Evaluating Current and Emerging Targeted Therapies in Hepatocellular Carcinoma Similar videos 19:03 Assessment of novel treatment options for patients with PV 00:52 REVEAL study: long-term analysis of ruxolitinib in patients with polycythemia vera after hydroxyurea 02:55 PV-AIM: using machine learning to predict resistance to hydroxyurea therapy in patients with PV 19:41 Recent advances in the diagnosis, prognosis and survival predictions of patients with PV 03:59 PV: outcomes, unmet needs, and therapeutic strategies 52:50 Use of Cytoreductive Therapy in Patients with Low Risk Polycythemia Vera 17:02 Indication for cytoreductive therapy in ET and PV: Do we have it right? 20:58 MPN Transformation to MDS and AML: Risk Factors, Therapy, and Outcomes 16:19 Latest on Current Treatments for Myelofibrosis, Polycythemia Vera, Essential Thrombocythemia 12:06 Can patients with Polycythemia Vera (PV) live a normal lifespan? 01:52 Advances in Polycythemia Vera Research 05:25 How can we predict and reduce the risk of thrombosis in a patient with PV? 18:50 JAK Inhibitors for ET and PV: What have we learned so far? 01:10 Polycythemia vera (PV): Presentations of elevated blood cell levels 23:44 2nd Line Therapy for Patients Diagnosed with Polycythemia Vera (PV) 12:24 Development of long-acting interferon as new therapy for PV and ET 01:09 Significance of Findings in RESPONSE Trial in Polycythemia Vera 17:54 "Patients are Asking", Q&A with MPN expert Dr. Abu-Zeinah, Ropeginterferon approved for treating PV. 20:53 Debate: Position of JAK2 inhibitors as second line therapy in Polycythemia vera More results